517 related articles for article (PubMed ID: 32027523)
1. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
[No Abstract] [Full Text] [Related]
2. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis.
Miyoshi J; Matsuura M; Hisamatsu T
Expert Opin Drug Saf; 2022 Jan; 21(1):1-8. PubMed ID: 34511011
[TBL] [Abstract][Full Text] [Related]
3. Role of ustekinumab in treatment of ulcerative colitis: a narrative review.
Grova M; Vitello A; Mannino M; Casà A; Renna S; Macaluso FS; Orlando A
Immunotherapy; 2023 Dec; 15(18):1539-1552. PubMed ID: 38018475
[TBL] [Abstract][Full Text] [Related]
4. Anti-interleukin-23 agents for the treatment of ulcerative colitis.
Hanžel J; D'Haens GR
Expert Opin Biol Ther; 2020 Apr; 20(4):399-406. PubMed ID: 31760827
[No Abstract] [Full Text] [Related]
5. Ustekinumab: a novel therapeutic option in Crohn's disease.
Simon EG; Samuel S; Ghosh S; Moran GW
Expert Opin Biol Ther; 2016 Aug; 16(8):1065-74. PubMed ID: 27341173
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
Deepak P; Loftus EV
Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
[TBL] [Abstract][Full Text] [Related]
7. Blockade of IL-23: What is in the Pipeline?
Parigi TL; Iacucci M; Ghosh S
J Crohns Colitis; 2022 May; 16(Supplement_2):ii64-ii72. PubMed ID: 35553666
[TBL] [Abstract][Full Text] [Related]
8. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
Wong U; Cross RK
Expert Opin Investig Drugs; 2019 May; 28(5):473-479. PubMed ID: 30884245
[TBL] [Abstract][Full Text] [Related]
9. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
10. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges.
Noviello D; Mager R; Roda G; Borroni RG; Fiorino G; Vetrano S
Front Immunol; 2021; 12():611256. PubMed ID: 34079536
[TBL] [Abstract][Full Text] [Related]
11. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease.
Almradi A; Hanzel J; Sedano R; Parker CE; Feagan BG; Ma C; Jairath V
BioDrugs; 2020 Dec; 34(6):713-721. PubMed ID: 33105016
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm.
D'Amico F; Peyrin-Biroulet L; Danese S
J Crohns Colitis; 2022 May; 16(Supplement_2):ii30-ii41. PubMed ID: 35553665
[TBL] [Abstract][Full Text] [Related]
13. Ustekinumab for treating ulcerative colitis: an expert opinion.
Biancone L; Ardizzone S; Armuzzi A; Castiglione F; D'Incà R; Danese S; Daperno M; Gionchetti P; Rizzello F; Scribano ML; Vecchi M; Orlando A
Expert Opin Biol Ther; 2020 Nov; 20(11):1321-1329. PubMed ID: 32662683
[TBL] [Abstract][Full Text] [Related]
14. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
15. Targeting IL-23 for IBD: Rationale and Progress to Date.
Vuyyuru SK; Shackelton LM; Hanzel J; Ma C; Jairath V; Feagan BG
Drugs; 2023 Jul; 83(10):873-891. PubMed ID: 37266801
[TBL] [Abstract][Full Text] [Related]
16. Ustekinumab for the treatment of Crohn's disease.
Hansen T; Targownik LE
Expert Rev Gastroenterol Hepatol; 2016 Sep; 10(9):989-94. PubMed ID: 27450626
[TBL] [Abstract][Full Text] [Related]
17. IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy.
Furfaro F; Gilardi D; Allocca M; Cicerone C; Correale C; Fiorino G; Danese S
Expert Rev Clin Immunol; 2017 May; 13(5):457-467. PubMed ID: 28067059
[TBL] [Abstract][Full Text] [Related]
18. Can IL-23 be a good target for ulcerative colitis?
Allocca M; Furfaro F; Fiorino G; Gilardi D; D'Alessio S; Danese S
Best Pract Res Clin Gastroenterol; 2018; 32-33():95-102. PubMed ID: 30060945
[TBL] [Abstract][Full Text] [Related]
19. A critical review of ustekinumab for the treatment of active ulcerative colitis in adults.
Vieujean S; Louis E; Danese S; Peyrin-Biroulet L
Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):413-430. PubMed ID: 36949608
[TBL] [Abstract][Full Text] [Related]
20. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
Deepak P; Sandborn WJ
Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
